ImmuniWeb
6.8#3 in web application security scannersFrom €595 a yearAndroidiOSWebAPI
VisitImmuniWeb vs Picus Security Platform
Picus Security Platform
6.1#8 in offensive securityWebAPILinuxmacOS
VisitWhat both publish
| Fact | ImmuniWeb | Picus Security Platform |
|---|---|---|
| Compliance | Discovery states that it helps address monitoring requirements under regulations and frameworks including GDPR, DORA, NIS 2, HIPAA, ISO 27001, SOC 2 and PCI DSS. | Picus states that it holds ISO/IEC 27001, ISO/IEC 27701, ISO/IEC 22301, and ISO/IEC 20000-1 certificates and a SOC 2 Type 2 report. |
| Founded | 2014 | 2013 |
| Headquarters | Geneva, Switzerland | Wilmington, Delaware, USA |
| Integrations | The maker lists integrations including GitHub Actions, GitLab CI/CD, Azure Pipelines, Jenkins, Asana, Jira, Slack, Splunk, Okta and Microsoft Teams. | Picus says it integrates with more than 75 security technologies across EDR, SIEM, NGFW, WAF, and email. |
| Support | Discovery packages include 24/7 expert assistance through a dedicated support system. | The free trial page says trial users can access Picus's knowledge base and ticket portal and request help with a guided proof of concept. |
ImmuniWeb plans
- ImmuniWeb Neuron — Monthly Scan Subscription€395 a month
- ImmuniWeb Neuron Mobile — Monthly Scan Subscription€395 a month
- ImmuniWeb Neuron — Annual Scan Subscription€595 a year
- ImmuniWeb Neuron Mobile — Annual Scan Subscription€595 a year
- ImmuniWeb Discovery — ASM package€1,495 a month
- ImmuniWeb Discovery — Dark Web package€1,495 a month
Picus Security Platform plans
- Free TrialFree
Pick ImmuniWeb if…
It may suit organizations that need application or API scans, penetration testing, or ongoing attack-surface monitoring. The no-cost Community Edition is aimed at SMEs, educational institutions, and small municipal governments seeking cybersecurity, privacy, and compliance checks.
Pick Picus Security Platform if…
Picus is aimed at security teams that want to validate controls, prioritize exposures, and focus remediation on critical gaps. Its trial is limited to one simulation agent and one technology’s recommendations.